Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial
Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial
复制标题
DOI：
10.1055/s-0028-1085438
复制
发表时间：
2009-01-01
影响因子：
4.3
通讯作者：
de Baptista, E. Araujo
中科院分区：
文献类型：
--
作者：
Baptista, T.;Rangel, N.;de Baptista, E. Araujo
前言：体重增加过多、高血糖、血脂异常是奥氮平的重要副作用。我们观察了罗格列酮对奥氮平治疗的精神分裂症患者体重、胰岛素抵抗指数(HOMA-IR)、血脂、糖化血红蛋白和纤维蛋白原的影响。方法：30例服用奥氮平的患者随机分为罗格列酮组(n=15：4~8 mg/d)和安慰剂组(n=15)，每组15例。结果：罗格列酮组和安慰剂组分别增加3.2+/-4.5 kg和2.2+/-2.3 kg(p=0.65)。罗格列酮治疗后胰岛素和HOMA-IR显著下降(p<0.05)。
Introduction: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.Methods: Thirty patients taking olanzapine (10-20mg daily for 8 months) were randomly allocated to rosiglitazone (n=15: 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12.Results: The rosiglitazone and placebo groups gained 3.2 +/- 4.5 and 2.2 +/- 2.3kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p